Bayer partners with Acura to license meth-resistant IMPEDE technology

PALATINE, Ill. — Acura Pharmaceuticals and Bayer Healthcare are partnering to develop a product with pseudoephedrine that would be resistant to being used in methamphetamine. Bayer will provide a worldwide license for Acura’s IMPEDE methamphetamine resistant technology for use in an undisclosed product with pseudoephedrine. The two companies will jointly develop it for the U.S. market.

The technology, which Acura currently implements in its Nexafed products, is able to reduce the yield of methamphetamine when compared to traditional formula medication. 

“We're excited to have a partner that brings highly valued development expertise and is committed to addressing the methamphetamine problem,” Acura’s president and CEO Bob Jones said.